[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Minerva Neuroscie (NERV)

Minerva Neuroscie (NERV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 273,943
  • Shares Outstanding, K 46,589
  • Annual Sales, $ 0 K
  • Annual Income, $ -293,420 K
  • EBIT $ -15 M
  • EBITDA $ -15 M
  • 60-Month Beta -0.08
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.18
  • Number of Estimates 1
  • High Estimate $-0.18
  • Low Estimate $-0.18
  • Prior Year $-0.43
  • Growth Rate Est. (year over year) +58.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.49 +2.55%
on 04/13/26
7.58 -25.73%
on 04/22/26
+0.12 (+2.18%)
since 04/10/26
3-Month
5.02 +12.15%
on 04/06/26
8.80 -36.02%
on 03/16/26
-0.70 (-11.06%)
since 02/11/26
52-Week
1.30 +333.08%
on 05/20/25
12.46 -54.82%
on 10/21/25
+4.02 (+249.69%)
since 05/09/25

Most Recent Stories

More News
Minerva Neurosciences: Q1 Earnings Snapshot

Minerva Neurosciences: Q1 Earnings Snapshot

NERV : 5.63 (-4.25%)
Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates

Confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated and first patient screened Previous open label trial data presented at SIRS 2026 showed no safety or drug–drug...

NERV : 5.63 (-4.25%)
Minerva Announces Leadership Transition

BURLINGTON, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous...

NERV : 5.63 (-4.25%)
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

Roluperidone has been de-risked by consistent positive results in two prior pivotal trials and remains the only late-stage drug candidate for this high-need population Efficacy topline data expected...

NERV : 5.63 (-4.25%)
Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026

Trial demonstrated no safety concerns when co-administering roluperidone and olanzapine The Company continues to advance the program, with the confirmatory Phase 3 trial now enrolling and topline...

NERV : 5.63 (-4.25%)
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum

BURLINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous...

NERV : 5.63 (-4.25%)
Minerva Neurosciences: Q4 Earnings Snapshot

Minerva Neurosciences: Q4 Earnings Snapshot

NERV : 5.63 (-4.25%)
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates

BURLINGTON, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...

NERV : 5.63 (-4.25%)
Minerva Neurosciences to Participate in The Citizens Life Sciences Conference

BURLINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous...

NERV : 5.63 (-4.25%)
Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026

BURLINGTON, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous...

NERV : 5.63 (-4.25%)

Business Summary

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The Company's pipeline will initially target the treatment of schizophrenia, major depressive...

See More

Key Turning Points

3rd Resistance Point 6.37
2nd Resistance Point 6.21
1st Resistance Point 5.92
Last Price 5.63
1st Support Level 5.47
2nd Support Level 5.31
3rd Support Level 5.02

See More

52-Week High 12.46
Fibonacci 61.8% 8.20
Fibonacci 50% 6.88
Last Price 5.63
Fibonacci 38.2% 5.56
52-Week Low 1.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.